



## **Multifunctional Immunotherapy To Treat Unresponsive Cancers**

**Genenovate Investors Day, 27<sup>th</sup> June 2025**



## Better Therapies Are Needed To Treat “Cold” Tumours



**Most patients don't respond to immunotherapy**

~ 60-70% of cancers  
are considered immunologically "cold"

**Only 5% Prostate Cancer Patients Respond to Checkpoint Inhibition**




# A Multifunctional Approach is Required

## *Multiple-therapies-in-one*

- ✓ ***Activate immune system***
- ✓ ***Personalised cancer vaccine***
- ✓ ***Delivery of multiple therapeutic payloads inside the tumour***

# Viral Immunotherapy - Stratosvir's Value Proposition




# How The Technology Works

- Virus evades elimination to reach tumour
- Virus selectively replicates in cancer cells

Stealth coat

Potent therapeutic  
payloads alter TME


- Cell killing
- Vaccine-like effect
- Immune response  
to patients' own  
tumour






# Platform Development and PoC for IV Delivery

Synthetic biology approach to bio-select stable vectors for in vivo use




## In vitro PoC

Viral persistence in human serum (in vitro)



## In vivo PoC


Viral persistence in plasma after IV delivery (rat model)



- ✓ IP owned by Stratosvir
- ✓ Innovate UK grant awarded



# Leaders in Tumour Antibody Delivery



## Proprietary Antibody Discovery Platform

- Therapeutic monoclonals delivery inside tumours.
- Building antibodies to match tumour's biology.
- Full ownership of product. No in-licensing, first mover potential.

- ✓ *Innovate UK-ZIM joint grant awarded*
- ✓ *Local (Brandenburg) collaboration partner*



# Opportunity Area - Prostate Cancer



**Prostate cancer  
affects 1 in 8 men**




**1 in 4  
die as a result**



**Patients need  
alternative drugs**



# Opportunity to Disrupt (Advanced) Prostate Cancer Therapy




- \$13.4B market (2024, CAGR 8.4%)
- Provenge (sipuleucel-T) \$551M, 2023
- Open to market disruption by a scalable, effective immunotherapy.

# Strategy – Use of Funds



- The ask: €1M to expand in vivo data package for Series A Round.



# Expert Team With Proven Track Record of Delivery



## **CEO - Chris Ullman PhD Co-founder**

- Experienced early stage CSO/CEO and BD, IP.
- Expert in engineering biology, virology, biologics discovery, delivery and preclinical translation.
- Inventor of 5 granted patents.



## **CSO – Antonio Postigo PhD Co-founder**

- Ex-Head of Virology, Psioxus.
- Expert in viral immunotherapy.
- Virologist (vaccinia, adenovirus) and cancer biologist.
- Discovery, translational biology and CMC.



## **Chair – Priya Mande–**

- Ex-President, CEO, COO Psioxus.
- Deputy Dir. UK Vaccine Taskforce.
- \$85M raised in equity and \$80M non-dilutive funding.
- Senior roles in Pharma
- Top 25 Global Women Leaders in Biotechnology Award 2020





Thank  
you!

[chris@stratosvir.com](mailto:chris@stratosvir.com)

## Vision and Value



Patients tell us they want **better** treatments with **lower** side-effects

Our *multiple-therapies-in-one* products are designed to give them that future.



Innovate  
UK

